The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)
Overtreatment more likely in younger, male, Hispanic or Asian patients, those with extensive lymph node surgery.
The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.
Researchers report on implementation of a nurse navigator and pretreatment care plans on time from diagnosis to treatment for patients with head and neck cancers.
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity.